Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hirashima

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)H Yoshioka, K Azuma, N Yamamoto, et al.
Diabetes, Obesity & Metabolism|August 23, 2002
Substitution of Dmo1 with normal alleles results in decreased manifestation of diabetes in OLETF ratsS Okuno, M Kondo, Y Yamasaki, et al.
Oncogene|November 19, 2008
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivityZ Tang, S Jiang, R Du, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)H Yoshioka, K Azuma, N Yamamoto, et al.
Diabetes, Obesity & Metabolism|August 23, 2002
Substitution of Dmo1 with normal alleles results in decreased manifestation of diabetes in OLETF ratsS Okuno, M Kondo, Y Yamasaki, et al.
Oncogene|November 19, 2008
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivityZ Tang, S Jiang, R Du, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)K Yamazaki, M Nagase, H Tamagawa, et al.
Pageof 9